Martin David Harp

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI

Academy’s program will take place in San Francisco, California, 3-6 November 2023, before returning to Chicago, Illinois in 2024

Every October, World Sight Day brings awareness to the global challenges of blindness and vision impairment

ARCATUS, also known as XIPERE®, utilises a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Nicholas Volpe, MD shares insights from his talk titled "Optic Neuropathy Versus Maculopathy" at the European Society of Ophthalmology Congress being held in Prague.

Dr Christiana Dinah discusses her SOE presentation, "Geographic Atrophy: A Mixed Method Study."

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

RAFARM and BioNanoSim have entered into an agreement to create the company.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone, talks about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Dr T.Y. Alvin Liu talks about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

Dr Carl Danzig, MD, FASRS, spoke at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

Dr Caroline Baumal talks about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Dr Deborah Ferrington talks about her ARVO presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.

Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, United States, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.